Amylyx Pharmaceuticals, Inc. (AMLX) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Engine safety override at $13.10: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 4.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Elevated put/call ratio: 7.60; Below-average business quality.
Amylyx Pharmaceuticals is a clinical-stage pharmaceutical company developing avexitide (Phase 3 LUCIDITY trial complete for post-bariatric hypoglycemia, topline data expected Q3 2026) and AMX0035 (Phase 2 for Wolfram syndrome). The company withdrew its previous commercial... Read more
Sell if holding. Engine safety override at $13.10: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 4.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Elevated put/call ratio: 7.60; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.8/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 58d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
About Amylyx Pharmaceuticals, Inc.
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals is advancing avexitide through the 75-participant Phase 3 LUCIDITY trial for post-bariatric hypoglycemia, with topline data expected in Q3 2026 and a commercial launch targeted for 2027 if the FDA approves. The company accumulated a $751.4 million deficit through December 31, 2025—following the 2024 voluntary market withdrawal of RELYVRIO/ALBRIOZA for ALS after the Phase 3 PHOENIX trial failed its primary and secondary endpoints—down from $380.8 million in RELYVRIO revenue generated in 2023.
Amylyx generates no product revenue following the withdrawal of RELYVRIO/ALBRIOZA; future revenue depends on regulatory approval and successful commercialization of pipeline assets. Avexitide targets post-bariatric hypoglycemia (PBH), estimated to affect roughly 8% of U.S. patients who have undergone the two most common bariatric surgeries—approximately 160,000 people in the U.S. The FDA granted avexitide Breakthrough Therapy Designation for both PBH and congenital hyperinsulinism, Rare Pediatric Disease Designation for congenital HI, and Orphan Drug Designation for hyperinsulinemic hypoglycemia. Manufacturing of all pipeline assets—avexitide, AMX0035, AMX0114, and AMX0318—is entirely outsourced to third-party CMOs; the company has no internal manufacturing capability. AMX0035, an oral fixed-dose combination of sodium phenylbutyrate and taurursodiol, is in open-label Phase 2 (HELIOS) for Wolfram syndrome, with positive Week 48 data announced in May 2025. AMX0114, an antisense oligonucleotide targeting calpain-2, entered Phase 1 in ALS with first participant dosing in April 2025.
Show full overview
Amylyx's near-term valuation is binary on the LUCIDITY topline readout expected Q3 2026: a successful outcome supports a U.S. NDA submission and a planned 2027 commercial launch, while a failure would eliminate the primary near-term revenue path. Five prior clinical trials in PBH—including the 28-day PREVENT Phase 2, which met its primary endpoint with a statistically significant 21% improvement in glucose nadir—form the evidentiary basis for Phase 3, but prior Phase 2 success has not protected the company before: PHOENIX failed despite encouraging Phase 2 data for ALS. The 10-K cautions that the PBH and congenital HI markets may be smaller than expected, adding commercial-size risk on top of trial outcome uncertainty.
See also: Healthcare · Drug Manufacturers - Specialty & Generic
From Amylyx Pharmaceuticals, Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-06-09Recent Developments — Amylyx Pharmaceuticals, Inc.
Latest news
- NEWS CORRECTION: Amylyx Pharmaceuticals Announced Results From Phase 2 Open-Label HELIOS Clinical Trial Of AMX0035 On May 15 — benzinga May 22, 2026 positive
- NEWS Amylyx Pharmaceuticals Publishes Data From Weeks 24, 48 Of Its Phase 2 HELIOS Study Of AMX0035 To Treat Wolfram Syndrome — benzinga May 15, 2026 positive
- NEWS 12 Health Care Stocks Moving In Friday's Pre-Market Session — benzinga May 8, 2026 neutral
- NEWS Amylyx Pharma Q1 EPS $(0.37), Inline, Cash, Cash Equivalents, And Short-Term Investments Were $279.8M, With Expected Cas — benzinga May 7, 2026 neutral
- NEWS Amylyx Launches Early Access Program For Experimental Hypoglycemia Drug, Expands Access To Avexitide Ahead Of Phase 3 Re — benzinga May 5, 2026 positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineavexitide10-K Item 1A: 'We currently depend heavily on the success of avexitide, our most advanced product candidate, and AMX0035.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Volatile — 5.8% daily ATR makes tight stops impractical. Position-size conservatively.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $13.10: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 4.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Elevated put/call ratio: 7.60; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $12.10. Score 4.8/10, moderate confidence.
Take-profit target: $20.36 (+56.5% upside). Prior stop was $12.10. Stop-loss: $12.10.
Concentration risk — Pipeline: avexitide; Quality below floor (1.2 < 4.0).
Amylyx Pharmaceuticals, Inc. trades at a P/E of N/A (forward -10.3). TrendMatrix value score: 9.0/10. Verdict: Sell.
18 analysts cover AMLX with a consensus score of 4.3/5. Average price target: $23.
What does Amylyx Pharmaceuticals, Inc. do?Amylyx Pharmaceuticals is a clinical-stage pharmaceutical company developing avexitide (Phase 3 LUCIDITY trial complete...
Amylyx Pharmaceuticals is a clinical-stage pharmaceutical company developing avexitide (Phase 3 LUCIDITY trial complete for post-bariatric hypoglycemia, topline data expected Q3 2026) and AMX0035 (Phase 2 for Wolfram syndrome). The company withdrew its previous commercial product RELYVRIO for ALS in 2024 and currently has no approved products or revenue.